000			03380nam a22006377a 4500
008			130912s20122012 xxu||||| |||| 00| 0 eng dOvid Technologies
022			_a1534-4827
040			_aOvid MEDLINE(R)
099			_a22037824
245			_aGestational diabetes: implications for cardiovascular health. [Review]
251			_aCurrent Diabetes Reports. 12(1):43-52, 2012 Feb.
252			_aCurr Diab Rep. 12(1):43-52, 2012 Feb.
253			_aCurrent diabetes reports
260			_c2012
260			_fFY2012
266			_d2013-09-17
520			_aGestational diabetes mellitus (GDM) is a pregnancy complication that is becoming more prevalent with recent population trends in obesity and advancing maternal age. A diagnosis of GDM not only increases risk for maternal and fetal complications during pregnancy, but also significantly increases a woman's risk of both type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) in the postpartum. Even women with milder forms of abnormal glucose homeostasis during pregnancy, specifically gestational impaired glucose tolerance, are at increased risk, justifying the recent recommendation to tighten the diagnostic criteria for GDM, thus implicating many more women. Risk factors that increase risk for future CVD among women with a history of GDM include postpartum progression to T2DM; metabolic syndrome; obesity; hypertension; and altered levels of circulating inflammatory markers, specifically, adiponectin, C-reactive protein, and tumor necrosis factor-. Medical therapies such as metformin that prevent progression to T2DM may prove to be our primary defense against earlier CVD among women with GDM.
546			_aEnglish
650			_a*Cardiovascular Diseases/et [Etiology]
650			_a*Diabetes Mellitus, Type 2/co [Complications]
650			_a*Diabetes, Gestational
650			_a*Diabetic Angiopathies/et [Etiology]
650			_a*Obesity/co [Complications]
650			_aBiological Markers/bl [Blood]
650			_aCardiovascular Diseases/dt [Drug Therapy]
650			_aCardiovascular Diseases/pc [Prevention & Control]
650			_aDiabetes Complications/et [Etiology]
650			_aDiabetes Mellitus, Type 2/dt [Drug Therapy]
650			_aDiabetes Mellitus, Type 2/pc [Prevention & Control]
650			_aDiabetes, Gestational/dt [Drug Therapy]
650			_aDiabetes, Gestational/pc [Prevention & Control]
650			_aDiabetic Angiopathies/dt [Drug Therapy]
650			_aDiabetic Angiopathies/pc [Prevention & Control]
650			_aDisease Progression
650			_aFemale
650			_aHumans
650			_aHypoglycemic Agents/tu [Therapeutic Use]
650			_aMaternal Age
650			_aMetformin/tu [Therapeutic Use]
650			_aObesity/pc [Prevention & Control]
650			_aPregnancy
650			_aPrevalence
650			_aRisk Assessment
650			_aRisk Factors
651			_aMedStar Health Research Institute
651			_aMedStar Washington Hospital Center
656			_aMedicine/Endocrinology
657			_aJournal Article
657			_aReview
700			_aRatner, Robert E
700			_aSullivan, Shannon D
700			_aUmans, Jason G
790			_aRatner R, Sullivan SD, Umans JG
856			_uhttp://dx.doi.org/10.1007/s11892-011-0238-3 _zhttp://dx.doi.org/10.1007/s11892-011-0238-3
942			_cART _dArticle
999			_c1350 _d1350